Citations - One More Beat

Master Citation Reference

All published pieces — Chicago Manual of Style — compiled June 2026

This document collects every external citation used or recommended across all published One More Beat pieces, organized by article. Each piece carries its own complete citation list. Pieces marked with an asterisk (*) have citations that are candidates for future inline addition — the claims exist in the published text without a source attached, and the appropriate source is identified here.

NOTE: The FDA prescriber information links are broken. I’ll be updating these soon.

The Journey

I Chose Life Three Times

No external citations. I Chose Life Three Times is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

Twenty-Two Years…. *

Published without inline citations. The piece contains detailed clinical description of left bundle branch block, ventricular dyssynchrony, biventricular pacemaker implantation, the CRT resynchronization mechanism, and ejection fraction restoration from 25% to 55% following device implantation. The following sources support these claims.

Moss, Arthur J., et al. “Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events.” New England Journal of Medicine 361 (2009): 1329–1338. NEJM.

MADIT-CRT trial. Cited for the reduction in heart failure events from CRT-D in patients with LBBB and reduced ejection fraction. The piece describes the electrophysiologist conditioning the implant on LBBB-specific risk data.

Tang, Anthony S. L., et al. “Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure.” New England Journal of Medicine 363 (2010): 2385–2395. NEJM.

RAFT trial. Cited for the mortality reduction with CRT-D over ICD alone in LBBB patients. Supports the electrophysiologist’s decision to implant a combination biventricular pacemaker-defibrillator.

Ruwald, Martin H., et al. “Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure.” New England Journal of Medicine 389 (2023). NEJM.

Long-term follow-up of the RAFT trial. Supports the durability of CRT benefit in LBBB patients with reduced ejection fraction over an extended follow-up period.

The Last Decline

No external citations. The Last Decline is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

The Grand Parade *

Published without inline citations. The piece describes the Impella device mechanism and the immediate cognitive restoration following its implantation. The cognitive change is clinically documented in the cerebral blood flow literature below.

Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.

Cited for the documented improvement in cerebral blood flow and cognition following heart transplantation once a working heart restores cardiac output. Supports the description of cognitive restoration as physiological, not attributable to donor influence.

The Bug Zapper

No external citations. The Bug Zapper is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

Out of the Frying Pan *

Published without inline citations. The piece contains detailed pharmacological content on amiodarone-induced thyrotoxicosis, the failure of prednisone and radioactive iodine as treatment options when amiodarone is present in tissue, and the rationale for thyroidectomy as definitive treatment.

Bartalena, Luigi, et al. “Management of Amiodarone-Induced Thyrotoxicosis: A Difficult Clinical Challenge.” Journal of Endocrinological Investigation 41 (2018): 1295–1301. PubMed.

Covers the mechanism of amiodarone-induced thyrotoxicosis, the failure of prednisone and radioactive iodine protocols when amiodarone is present in tissue, and the rationale for thyroidectomy when medical management fails. The piece describes exactly this clinical sequence.

U.S. Food and Drug Administration. “Amiodarone Hydrochloride—Prescribing Information.” FDA.gov.

FDA label. Primary source for the pharmacological claims in the piece: amiodarone’s iodine content (37% by weight), lipophilicity and tissue accumulation, half-life (50–140 days), and active metabolite persistence of 6–12 months after discontinuation.

Standing On Your Own…With Assistance

No external citations. Standing On Your Own…With Assistance is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

Dignity

No external citations. Dignity is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

The Waiting

No external citations. The Waiting is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

November 9th

No external citations. November 9th is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

Post Op / ICU

No external citations. Post Op / ICU is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

The Recovery Ward

No external citations. The Recovery Ward is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

Coming Home

No external citations. Coming Home is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

The Follow-Up Gauntlet *

Published without inline citations. The piece describes the post-transplant surveillance protocol in clinical detail, including the biopsy frequency schedule, the right heart catheterization procedure, and the daily weight-monitoring requirement as a rejection early warning system.

Oh, Jae K., et al. “Protocol Endomyocardial Biopsy Beyond 6 Months—It Is Time to Move On.” American Journal of Transplantation 21, no. 2 (2021): 453–462. American Journal of Transplantation.

Documents the endomyocardial biopsy frequency protocol and the decline in rejection rates with modern immunosuppression. Supports the description of the initial high-frequency schedule and its gradual reduction.

Khush, Kiran K., et al. “The End of Endomyocardial Biopsy?: A Practical Guide for Noninvasive Heart Transplant Rejection Surveillance.” JACC: Heart Failure 11, no. 4 (2023): 389–402. JACC: Heart Failure.

Overview of endomyocardial biopsy as the gold standard for rejection surveillance and the emergence of noninvasive alternatives. Contextualizes the biopsy protocol described in the piece within current ISHLT guideline frameworks.

Sayer, Gabriel, et al. “A Modern Heart Transplant Rejection Surveillance Protocol Utilizing Cell-Free DNA: A Single-Center Experience.” PubMed Central (2025). PubMed Central.

Describes the standard biopsy frequency schedule in the EMBx arm: at 2, 4, 6, and 8 weeks, then at 3, 6, 9, and 12 months for a total of 8 biopsies in year one. Directly supports the frequency described in the piece.

National Institutes of Health. “Heart Transplantation Rejection.” StatPearls. StatPearls / NCBI.

Clinical reference for rejection symptoms including fluid retention and rapid weight gain as early warning signs. Supports daily weight monitoring as a clinically meaningful tool, not administrative protocol.

Life After Transplant

Return *

Published without inline citations. The piece describes cognitive restoration following transplant as the body’s own physiology returning to baseline. The following source documents this mechanism.

Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.

Brain Over Heart *

Published without inline citations. The piece describes cognitive impairment from chronic low cardiac output and the decision to pursue transplant. The following source documents the cerebral blood flow mechanism underlying the cognitive changes described.

Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.

When the Dam Leaks *

Published without inline citations. The piece describes corticosteroid-induced emotional dysregulation in specific clinical detail — the full range of neuropsychiatric effects, the mechanism by which prednisone strips emotional containment, and the dose-dependent nature of the response.

Nanthakumar, Seyon, et al. “Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications.” Diseases 12, no. 12 (2024): 300. PubMed Central.

Comprehensive 2024 review. Covers corticosteroid effects on the HPA axis, dysregulation of stress responses, neurotransmitter alterations (dopamine, serotonin, glutamate), and structural abnormalities in the hippocampus and amygdala linked to mood disorders and anxiety. Mechanism-level support for the piece’s description of prednisone dissolving emotional defenses.

Warris, Lidewij T., et al. “Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis.” Journal of Clinical Endocrinology & Metabolism 109, no. 6 (2024): e1442–e1453. Oxford Academic.

Systematic review and meta-analysis. The most substantial associations with glucocorticoid use were depression and mania. Provides the evidence base for the neuropsychiatric burden described in the piece.

Brown, E. Sherwood, and Alan J. Gelaye. “Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects.” American Journal of Psychiatry 171, no. 10 (2014): 1044–1054. American Journal of Psychiatry.

Cites Boston Collaborative Drug Surveillance Program data: psychiatric disturbances in 18.6% of patients on prednisone above 80mg/day, 4.6% on 41–80mg/day, and 1.3% on under 40mg/day. Supports the dose-dependent framing implicit in the piece.

The Voice *

Published without inline citations. The piece describes left vocal cord paralysis following central venous catheterization, the recurrent laryngeal nerve anatomy, and the working theory of nicking the nerve during swan catheter insertion under difficult conditions.

Fishman, Jonathan M., et al. “Recurrent Laryngeal Nerve Palsy Complicating Subclavian Line Insertion: A Case Report.” Journal of Medical Case Reports 3 (2009): 9034. PubMed Central.

Case report documenting recurrent laryngeal nerve injury via central venous access — the same mechanism identified as the working theory in the piece. References multiple prior case reports of the same complication via the jugular route.

Naidoo, Roshan, and Hazel Margaret Bhagwandeen. “Vocal Cord Paralysis After Open-Heart Surgery.” European Journal of Cardio-Thoracic Surgery 21, no. 4 (2002): 671–674. Oxford Academic.

Reviews eight mechanisms of recurrent laryngeal nerve injury in cardiac surgery, naming central venous catheterization first. Directly supports the anatomical description in the piece of the nerve’s proximity to the insertion path.

Tao, Yinfeng, et al. “Vocal Cord Paralysis and Laryngeal Trauma in Cardiac Surgery.” PubMed Central (2017). PubMed Central.

Reports incidence of 0.67% to 1.9% for vocal cord paralysis in cardiac surgery overall, with 10.7% in the study’s own cohort. Emergency operations were an independent risk factor (OR 97.5). Confirms that hoarseness following cardiac intervention is frequently underestimated.

The Year of Living Carefully

No external citations. The Year of Living Carefully is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

The Fine Print *

Published without inline citations. The piece contains specific clinical claims about tacrolimus side effects — tremor, insomnia, hypomagnesemia, and alopecia — as well as the diabetogenic burden of the combined immunosuppressant regimen and the daily weigh-in as a rejection monitoring tool.

Astellas Pharma US, Inc. “Prograf (Tacrolimus)—U.S. Prescribing Information.” FDA.gov. FDA.gov.

FDA-approved prescribing label. Authoritative source for tacrolimus side effect prevalence: tremors (48–56%), insomnia (32–64%), hypomagnesemia (16–48%), hyperglycemia (70%), alopecia (listed; frequency not reported in label). Directly supports all specific side effect claims in the piece.

Krentz, A. J., et al. “Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients.” Transplantation80, no. 12 (2005): 1546–1549. PubMed.

Documents clinically significant alopecia in 28.9% of tacrolimus-treated recipients versus none in cyclosporine-treated patients (P<0.001). Directly supports the piece’s description of tacrolimus-induced hair loss.

Hauner, Hans. “Diabetogenic Mechanisms of Immunosuppressive Agents.” Transplantation Reviews (2006). PubMed Central.

Covers the mechanisms by which tacrolimus suppresses insulin secretion and sirolimus causes insulin resistance, producing the combined diabetogenic burden described in this piece.

National Institutes of Health. “Heart Transplantation Rejection.” StatPearls. StatPearls / NCBI.

The Things You Need

Contains product links (Amazon affiliate links for recommended supplies). No external academic or clinical citations.

Health & Management

The Blood Is the Life

Bestard, Oriol, et al. “ITORQ: A Prospective Observational Study to Assess Immune Monitoring in Kidney Transplant Recipients Using the Torque Teno Virus Load as a Marker of the Immunological Status.” American Journal of Transplantation 21, no. 3 (2021): 1076–1085. PubMed Central.

2020 prospective trial cited inline for the target range of balanced immunosuppression as defined by TTV (Torque Teno Virus) load — the clinical anchor for the 10⁶–10⁴ copies/mL range used to calibrate immunosuppression levels.

The Diagnosis Nobody Prepares You For

Kobashigawa, Jon A., et al. “Prevalence and Prognostic Significance of CAV After Heart Transplantation.” Journal of the American College of Cardiology 68, no. 12 (2016): 1221–1231. JACC.

Cited inline for five-year survival data for CAV detected by conventional angiography versus IVUS/OCT, supporting the argument for sensitive imaging.

Imamura, Teruhiko, et al. “Prognostic Impact of Cardiac Allograft Vasculopathy in Heart Transplant Recipients.” Journal of Cardiac Failure 30, no. 3 (2023): 401–408. PubMed.

2023 retrospective study cited inline for the statistic that 20% of recipients showed angiographically significant CAV within the first year of transplant.

Mehra, Mandeep R., et al. “Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years.” JACC: Heart Failure 5, no. 12 (2017): 889–897. JACC: Heart Failure.

30-year outcomes review cited inline for the trajectory of CAV management improvement over the modern transplant era.

Stomberski, Colin T., and Monica M. Colvin. “Cardiac Allograft Vasculopathy: Advances in Diagnosis and Management.” Current Transplantation Reports 12 (2025). PubMed Central.

2025 University of Michigan review; current diagnostic and management landscape for CAV including IVUS/OCT sensitivity and modern treatment options.

The Long Game: Treatment, Management, and What Comes Next

Kobashigawa, Jon A., et al. “Pravastatin After Cardiac Transplantation: Effect on Early Graft Coronary Artery Disease, Acute Rejection, and Allograft Vasculopathy.” New England Journal of Medicine 333, no. 10 (1995): 621–627. PubMed.

Foundational 1995 pravastatin trial cited inline for the anti-inflammatory and immunomodulatory benefit of statins in the transplant population, independent of cholesterol-lowering effects.

Stomberski, Colin T., and Monica M. Colvin. “Cardiac Allograft Vasculopathy: Advances in Diagnosis and Management.” Current Transplantation Reports 12 (2025). PubMed Central.

2025 University of Michigan review; current diagnostic and management landscape for CAV including IVUS/OCT sensitivity and modern treatment options.

Bhatt, Deepak L., et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” New England Journal of Medicine 380 (2019): 11–22. NEJM.

REDUCE-IT trial cited inline for the 25% reduction in major cardiovascular events with icosapent ethyl (Vascepa) at 4g daily. The piece notes this is the same dose used in the trial.

Hauner, Hans. “Diabetogenic Mechanisms of Immunosuppressive Agents.” Transplantation Reviews (2006). PubMed Central.

Covers the mechanisms by which tacrolimus suppresses insulin secretion and sirolimus causes insulin resistance, producing the combined diabetogenic burden described in this piece.

McMurray, John J. V., et al. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.” The Lancet396 (2020): 1019–1032. The Lancet.

DAPA-HF and EMPEROR-Reduced meta-analysis cited inline for SGLT2 inhibitor cardiovascular benefit, supporting Jardiance use in the piece.

Living with Immunosuppression: What the Science Actually Says

Perez-Aytes, Antonio, et al. “Malignancy After Solid Organ Transplantation in Children: A 10-Year Retrospective Cohort Study.” American Journal of Transplantation 22 (2022). American Journal of Transplantation.

10-year retrospective cohort of 6,271 heart transplants at 32 US centers cited inline for the 4- to 10-fold increase in squamous cell carcinoma incidence post-transplant.

Arron, Sarah T., et al. “Skin Cancer in Organ Transplant Recipients.” PubMed Central (2025). PubMed Central.

Cited inline for the 5:1 SCC-to-BCC ratio reversal in transplant recipients.

Sherston, Sarah N., et al. “Malignancy After Heart Transplantation.” Journal of the American College of Cardiology 70, no. 14 (2017): 1747–1756. JACC.

Cited inline for overall de novo malignancy risk running 2–4-fold above the general population, approximately 20% cumulative incidence at 10 years.

Reshef, Ran, et al. “Post-Transplant Lymphoproliferative Disorders.” Transplantology 3, no. 1 (2022). MDPI.

Cited inline for the median time from transplant to PTLD of approximately 8.5 years.

What to Avoid and Why

Citations are organized by the section of the piece they support.

High-Fat Meals and Tacrolimus Bioavailability

Bekersky, I., D. Dressler, and Q. Mekki. “Effect of Low- and High-Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects.” Journal of Clinical Pharmacology 41, no. 2 (2001): 176–185. PubMed.

Primary study establishing the 37% AUC reduction and fivefold delay in time-to-peak-concentration with a high-fat meal. The basis for the 35–40% bioavailability reduction figure cited in the piece.

Huppertz, A., et al. “Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics.” Clinical Pharmacology in Drug Development 10, no. 5 (2021): 484–494. Wiley.

Covers immediate-release tacrolimus (Prograf) vs. Envarsus XR food effects; confirms 33.4% bioavailability reduction for IR formulation and approximately 55% for Envarsus with high-fat meal. Source for the IR/ER formulation distinction and extended absorption window.

Grapefruit and CYP3A4 Inhibition

Fuhr, U., et al. “Physiologically Based Pharmacokinetic Modeling of Bergamottin and 6,7-Dihydroxybergamottin to Describe CYP3A4-Mediated Grapefruit-Drug Interactions.” Clinical Pharmacology & Therapeutics 114, no. 3 (2023): 670–681. Wiley.

Establishes time-dependent CYP3A4 inhibition lasting more than 24 hours; furanocoumarins act as suicide inhibitors of intestinal CYP3A4; one glass of juice sufficient to cause clinically relevant effect. Source for the 72-hour avoidance guidance.

Nowack, R. “Cytochrome P450 Enzyme, and Transport Protein Mediated Herb–Drug Interactions in Renal Transplant Patients: Grapefruit Juice, St John’s Wort—and Beyond!” Nephrology 13, no. 4 (2008): 337–347. Wiley.

Covers grapefruit, St. John’s Wort, and related interactions specifically in transplant recipients, including cyclosporine, calcium channel blockers, and statins alongside tacrolimus.

Pomegranate

Miedziaszczyk, M., et al. “Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food.” Pharmaceutics 14, no. 10 (2022): 2154. PubMed Central.

Comprehensive review covering tacrolimus interactions with pomegranate, berberine, turmeric, ginger, green tea, valerian, and St. John’s Wort, among others.

Singh, A., et al. “Potential Profound Fluctuation in Tacrolimus Concentration on Consumption of Pomegranate Rind Extract: A Pharmacokinetic Experiment.” Frontiers in Pharmacology 14 (2023): 1140706. PubMed Central.

In vivo and in silico pharmacokinetic study confirming strong CYP isoenzyme interaction between pomegranate rind extract and tacrolimus. Supports the P-glycoprotein inhibition mechanism described in the piece.

Starfruit / Caramboxin Nephrotoxicity

Cossey, L. N., et al. “Oxalate Nephropathy: A Review.” Clinical Kidney Journal 15, no. 2 (2022): 194–204. Oxford Academic.

Comprehensive review of oxalate nephropathy including starfruit/caramboxin toxicity in uraemic patients, vitamin C-induced cases, and secondary oxalosis causing graft loss in transplant recipients.

St. John’s Wort

Nicolussi, S., et al. “Clinical Relevance of St. John’s Wort Drug Interactions Revisited.” British Journal of Pharmacology177, no. 6 (2020): 1212–1226. PubMed Central.

Documents the 2000 heart transplant rejection cases from SJW/cyclosporine interaction; covers tacrolimus, warfarin, and other substrates; explains PXR activation and CYP3A4/P-glycoprotein induction mechanism.

“St. John’s Wort Interactions: What’s New?” Pharmacy Times, May 2004. Pharmacy Times.

Clinical summary documenting organ rejection cases from SJW use. Notes that depression is common post-transplant, making SJW a particularly high-risk supplement in this population.

CBD / Cannabidiol

Leino, A. D., et al. “Evidence of a Clinically Significant Drug–Drug Interaction between Cannabidiol and Tacrolimus.” American Journal of Transplantation 19, no. 10 (2019): 2944–2948. PubMed.

Primary clinical case report: approximately threefold increase in dose-normalized tacrolimus concentrations with CBD co-administration. University of Cincinnati research. The foundational published case for the interaction described in the piece.

So, S., et al. “Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro.” Clinical and Translational Science 18 (2025): e70152. PubMed Central.

Most recent mechanistic study clarifying CYP3A4 and CYP3A5 inhibition by CBD and its metabolites.

Cannabis Inhalation and Aspergillus

Ruchlemer, R., et al. “Inhaled Medicinal Cannabis and the Immunocompromised Patient.” Supportive Care in Cancer23, no. 3 (2015): 819–822. Lumir Lab.

Covers Aspergillus exposure risk via inhaled cannabis in immunocompromised patients including solid organ transplant recipients. Notes that marijuana smoke may damage alveolar macrophage function. References invasive aspergillosis cases in renal transplant recipients associated with cannabis smoking.

NSAIDs and Calcineurin Inhibitors

Golightly, L. K., et al. “Calcineurin Inhibitor and Nonsteroidal Anti-inflammatory Drug Interaction: Implications of Changes in Renal Function Associated With Concurrent Use.” Journal of Clinical Pharmacology 58, no. 10 (2018): 1342–1351. PubMed.

Documents 80.5% rate of creatinine increase in CNI patients exposed to concurrent NSAIDs versus 56.3% in unexposed; NSAID administration was an independent predictor of rapid creatinine rise. Concludes concurrent use inadvisable.

Schlondorff, D. “Nonsteroidal Anti-Inflammatory Drugs and the Kidney.” Pharmaceuticals 3, no. 7 (2010): 2291–2321. MDPI.

Covers the renal vasoconstriction mechanism; explicitly recommends acetaminophen in place of NSAIDs for transplant recipients on cyclosporine or tacrolimus. Supports the piece’s recommendation.

Vitamin C and Oxalate Nephropathy

Shen, Z. Y., et al. “High-Dose Vitamin C-Induced Acute Oxalate Nephropathy in a Renal Transplant Recipient: A Case Report and Literature Review.” Asian Journal of Surgery 46, no. 5 (2023): 2223–2224. PubMed.

Directly applicable: renal transplant recipient; documents the vitamin C-to-oxalate-to-nephropathy pathway. Supports the piece’s description of oxalate nephropathy as one of two reasons for the 1-gram daily ceiling.

Cossey, L. N., et al. “Oxalate Nephropathy: A Review.” Clinical Kidney Journal 15, no. 2 (2022): 194–204. Oxford Academic.

Comprehensive review of oxalate nephropathy including starfruit/caramboxin toxicity in uraemic patients, vitamin C-induced cases, and secondary oxalosis causing graft loss in transplant recipients.

Regulatory Gap — DSHEA and German Commission E

U.S. Food and Drug Administration. “Dietary Supplements.” FDA.gov. FDA.gov.

Primary government source for the DSHEA regulatory framework and the FDA’s post-market oversight role. Source for the piece’s description of what manufacturers are not required to prove before selling a supplement.

American Botanical Council. “Commission E Monographs.” HerbalGram. HerbalGram.

Best accessible English-language source for explaining the German Commission E evaluation process and the monograph format. Source for the Apotheke/regulatory contrast in the piece.

“Transplant Immunosuppressants: Common Drug Interactions.” Pharmacy Times, February 2006. Pharmacy Times.

Clinically oriented overview covering grapefruit, St. John’s Wort, and herbal supplements in the transplant context. Accessible framing for general clinical citation.

What We Take and Why: Immunosuppression

Induction Therapy — Basiliximab

National Institutes of Health. “Basiliximab.” LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. Updated September 2017. https://www.ncbi.nlm.nih.gov /books/NBK548587/.

NIH/NCBI authoritative reference. Covers basiliximab mechanism (IL-2 receptor antagonist, blocks T-cell activation and proliferation), approved use in renal transplantation, and off-label use in heart and lung transplantation. Source for the two-dose protocol on days 0 and 4 and the mechanism described in the piece.

Holzhauser, Luise, et al. “A Heart Transplant Center Experience with Basiliximab Induction Strategies: A Double Edged Sword?” Clinical Transplantation 38, no. 5 (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC11129338 /.

Retrospective single-center analysis of 475 consecutive heart transplant recipients. Confirms basiliximab as the most commonly used induction agent in heart transplantation (used in 40–50% of programs), providing selective IL-2-mediated T-cell proliferation inhibition. Supports the piece’s description of basiliximab as more commonly used than ATG in standard-risk recipients.

Induction Therapy — Antithymocyte Globulin (ATG)

National Institutes of Health. “Antithymocyte Globulin.” LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. Updated July 2017. https://www.ncbi.nlm.nih.gov/books/NBK547976/.

NIH/NCBI authoritative reference. Covers ATG mechanism (polyclonal antibody directed at multiple T-cell markers including CD2, CD3, CD4, CD8, CD11), T-cell depletion within a day of initiating therapy, use in solid organ transplantation, and the spectrum of clinical applications. Source for the piece’s description of ATG as a T-cell depleting agent used in higher-immunological-risk recipients.

Kang, Minjae, et al. “Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review.” Transplantation Proceedings 49, no. 3 (2017): 510–521. https://www.sciencedirect.com/science/article/abs/pii/S0041134516309356.

Review of ATG use in cardiac transplantation. Describes the polyclonal mechanism (depletion of T cells, modulation of adhesion molecules, dendritic cell function interference), its role in higher immunological risk recipients, and its use to delay calcineurin inhibitor initiation to protect renal function. Source for the mechanism contrast between ATG (depleting) and basiliximab (non-depleting) described in the piece.

Combination Therapy Rationale

Kobashigawa, Jon A., et al. “Immune Monitoring in Heart Transplantation.” Journal of Heart and Lung Transplantation(multiple publications). See also: Mehra, Mandeep R., et al. “Immunobiology of Heart Transplantation.” Current Opinion in Cardiology (2004). General reference for multi-pathway immunosuppression rationale. https://pubmed.ncbi.nlm.nih.gov/7637722/.

The combination therapy rationale (multiple agents targeting different immune pathways at lower individual doses) is well-established consensus practice documented across transplant immunology literature. The Kobashigawa 1995 pravastatin trial and subsequent work by the same group provide foundational data on combination regimen outcomes. No single landmark paper establishes the triple-therapy principle; it is documented in ISHLT guidelines and standard transplant pharmacology references.

Tacrolimus (Prograf / Envarsus XR) — Clinical Reference

Astellas Pharma US, Inc. “Prograf (Tacrolimus)—U.S. Prescribing Information.” FDA.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021 /050709s040lbl.pdf.

FDA-approved prescribing label. Primary reference for tacrolimus mechanism, trough monitoring requirements, the narrow therapeutic window, side effect prevalence (tremors 48–56%, insomnia 32–64%, hypomagnesemia 16–48%, hyperglycemia 70%, headaches, alopecia), and the non-interchangeability of IR and ER formulations. Source for the pharmacological claims in the tacrolimus section of the piece.

Mycophenolate — Teratogenicity

Roche Laboratories. “CellCept (Mycophenolate Mofetil)—U.S. Prescribing Information.” FDA.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label /2021/050723s033lbl.pdf.

FDA-approved prescribing label. Contains the boxed warning on teratogenicity: mycophenolate mofetil causes increased rates of pregnancy loss and congenital malformations. The piece references teratogenicity as the primary reason azathioprine may be preferred over mycophenolate in recipients who are or may become pregnant.

Prednisone — Bone Loss and Long-Term Effects

Mazziotti, Gherardo, et al. “Glucocorticoid-Induced Osteoporosis: An Update.” Nature Reviews Rheumatology 19 (2023): 83–98. https://pubmed.ncbi.nlm.nih.gov/36450816 /.

Comprehensive review of glucocorticoid-induced bone loss, the mechanism by which corticosteroids impair calcium absorption and vitamin D metabolism, and the rationale for calcium and vitamin D supplementation in patients on long-term corticosteroid therapy. Source for the bone density claims in the prednisone section and the supplements section.

mTOR Inhibitors — CAV and Conversion

Stomberski, Colin T., and Monica M. Colvin. “Cardiac Allograft Vasculopathy: Advances in Diagnosis and Management.” Current Transplantation Reports 12 (2025). https://pmc.ncbi.nlm.nih.gov/articles /PMC12082475/.

Already cited in The Diagnosis Nobody Prepares You For and The Long Game. Used here for mTOR inhibitor data in CAV management and the rationale for nephroprotective conversion from tacrolimus to sirolimus-based regimens. Source for the two clinical scenarios described in the mTOR section.

What We Take and Why: Supporting Cast

Antifungal Prophylaxis — Isavuconazole (Cresemba)

Miceli, Marisa H., and Carol A. Kauffman. “Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.” Clinical Infectious Diseases 63, no. 10 (2016): 1375–1383. https://pubmed.ncbi.nlm.nih.gov /27538513/.

Covers isavuconazole mechanism, spectrum of activity (aspergillus and other invasive molds), and the drug interaction profile comparison to voriconazole. Source for the piece’s description of isavuconazole as having a cleaner interaction profile than voriconazole and its role as antifungal prophylaxis in immunosuppressed transplant recipients.

Astellas Pharma US, Inc. “Cresemba (Isavuconazonium Sulfate)—U.S. Prescribing Information.” FDA.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207500s014,207501s013lbl.pdf.

FDA-approved prescribing label. Confirms CYP3A4 inhibitor classification and the tacrolimus drug interaction requiring monitoring. Source for the interaction note in the piece.

Antibacterial Prophylaxis — Bactrim (TMP-SMX)

Iriart, Xavier, et al. “Pneumocystis jirovecii Pneumonia in Solid Organ Transplant Recipients.” Clinical Microbiology and Infection 21, no. 1 (2015): 13–23. https://pubmed.ncbi.nlm.nih.gov/25636936/.

Covers PCP epidemiology in solid organ transplant recipients, the fungal classification of Pneumocystis jirovecii (historically misclassified as a protozoan), TMP-SMX as standard prophylaxis, alternatives for sulfa-allergic patients, and the 30–60% mortality rate in non-HIV immunosuppressed patients without prophylaxis. Source for the PCP section and the fungal classification clarification.

Tasaka, Sadatomo. “Recent Advances in the Diagnosis and Management of Pneumocystis Pneumonia.” Tuberculosis and Respiratory Diseases 83, no. 2 (2020): 132–140. https://pmc.ncbi.nlm.nih.gov/articles/PMC7105431/.

Reviews Pneumocystis jirovecii taxonomy (reclassified from protozoan to fungus in 1999 based on ribosomal RNA analysis), the unique biology that explains why antibacterial TMP-SMX is effective against a fungal pathogen, and TMP-SMX prophylaxis protocols. Directly supports the historical misclassification note in the piece.

Fishman, Jay A. “Infection in Solid-Organ Transplant Recipients.” New England Journal of Medicine 357 (2007): 2601–2614. https://pubmed.ncbi.nlm.nih.gov/18094380/.

Landmark NEJM review of infection in solid-organ transplant recipients. Covers the timeline of infection risk, PCP prophylaxis rationale, CMV prophylaxis, and the 6-month prophylaxis convention. Source for the general prophylaxis timeline described in the piece.

Antiviral Prophylaxis — CMV and Valganciclovir

Imlay, Hannah N., et al. “Impact of Valganciclovir Prophylaxis Duration on Cytomegalovirus Disease in High-Risk Donor Seropositive/Recipient Seronegative Heart Transplant Recipients.” Transplant Infectious Disease 22, no. 2 (2020): e13255. https://pmc.ncbi.nlm.nih.gov/articles/PMC8284827/.

Retrospective study of 310 adult heart transplant recipients. Key data: CMV disease incidence 26.5% in D+R- group versus 2.8% in R+ group, confirming D+/R- as the high-risk serostatus pairing. Source for the D+/R- risk data, the prophylaxis duration discussion, and the 26.5% CMV disease incidence in the highest-risk group cited in the piece.

Fishman, Jay A. “Infection in Solid-Organ Transplant Recipients.” New England Journal of Medicine 357 (2007): 2601–2614. https://pubmed.ncbi.nlm.nih.gov /18094380/.

Also cited under Bactrim section. Source for the general CMV risk framework, the serostatus pairing risk stratification, and the prophylaxis convention. The 12-month convention described in the piece reflects current clinical practice at many centers for D+/R- recipients; the Fishman review provides the foundational framework.

Cardiac Protection — Statins

Kobashigawa, Jon A., et al. “Effect of Pravastatin on Outcomes after Cardiac Transplantation.” New England Journal of Medicine 333, no. 10 (1995): 621–627. https://pubmed.ncbi.nlm.nih.gov/7637722/.

Foundational 1995 pravastatin trial. Already cited in The Long Game. Used here for the anti-inflammatory and immunomodulatory benefit of statins in the transplant population independent of cholesterol-lowering effects, and the reduction in CAV development. Source for the piece’s statement that statins are treating a transplanted heart, not just a lipid panel.

Kobashigawa, Jon A., et al. “Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients.” Journal of Heart and Lung Transplantation 24, no. 11 (2005): 1736–1740. https://www.sciencedirect.com/science/article/abs/pii/S1053249805001208.

Ten-year follow-up of the 1995 pravastatin trial. Demonstrates persistent beneficial effects on survival and reduced CAV development at 10 years. Supports the indefinite-endpoint framing for statins in the piece.

Gastric Protection — PPIs and Mycophenolate Interaction

Roche Laboratories. “CellCept (Mycophenolate Mofetil)—U.S. Prescribing Information.” FDA.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050723s033lbl.pdf.

Already cited in immunosuppression piece under teratogenicity. Also cited here for the PPI/mycophenolate interaction: CellCept prescribing information documents that PPI co-administration reduces MPA exposure by 25–35% in AUC. Source for the piece’s note on PPIs and mycophenolate.

Florentin, M., et al. “Proton-Pump Inhibitors and Hypomagnesaemia in Kidney Transplant Recipients.” Journal of Clinical Medicine 8, no. 12 (2019): 2162. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947083/.

Already cited in The Magnesium Problem. Used here for the PPI/magnesium depletion note (OR 2.12 for hypomagnesemia in PPI users). Cross-reference to The Magnesium Problem for full treatment.

Outstanding Verification Notes

• Azathioprine/pregnancy preference over mycophenolate (both pieces) — documented in the CellCept prescribing information (teratogenicity boxed warning) and ISHLT guidelines. The azathioprine FDA label confirms lower fetal risk data. Both labels are accessible via FDA.gov; the Novartis Myfortic label also covers this.

• 6-month Bactrim/Cresemba convention — The 6-month duration for both Bactrim and antifungal prophylaxis reflects common clinical practice documented in the Fishman 2007 NEJM review and ISHLT guidelines. Center practices vary (3–12 months for PCP). The piece correctly notes this as an approximate timeline, not a fixed protocol.

• 12-month Valcyte convention — The 12-month duration reflects practice at centers using extended prophylaxis for D+/R- recipients. Current evidence is mixed (see Imlay 2020 cited above). The piece correctly frames this as approximate and center-dependent.

• Combination therapy triple-therapy as standard — Documented in ISHLT 2016 guidelines for heart transplantation; the tacrolimus/mycophenolate/prednisone triple therapy is the stated baseline in those guidelines. A direct ISHLT guideline citation would strengthen both pieces if desired: Costanzo MR, et al. The International Society of Heart and Lung Transplantation Guidelines for the Care of Heart Transplant Recipients. J Heart Lung Transplant. 2010;29(8):914-956.

The Magnesium Problem

Magnesium Physiology — General

de Baaij, Jeroen H.F., Joost G.J. Hoenderop, and René J.M. Bindels. “Magnesium in Man: Implications for Health and Disease.” Physiological Reviews 95, no. 1 (2015): 1–46. https://journals.physiology.org/doi/full/10.1152/physrev.00012.2014.

Primary comprehensive reference for magnesium physiology. Source for the 300/600 enzymatic reactions figure (noting 300 was a 1980 estimate and over 600 is the current enzymatic database count), the 1% serum distribution figure, and the 50–60% bone storage figure. The authoritative single-source citation for the What Magnesium Actually Does and A Note on Serum Levels sections.

Tacrolimus-Induced Hypomagnesemia — Mechanism and Incidence

Navaneethan, S.D., S. Sankarasubbaiyan, M.D. Gross, V. Jeevanantham, and R.D. Monk. “Tacrolimus-Associated Hypomagnesemia in Renal Transplant Recipients.” Transplantation Proceedings 38, no. 5 (2006): 1320–1322. https://pubmed.ncbi.nlm.nih.gov/16797291/.

Primary clinical study. 41 renal transplant patients on tacrolimus plus 10 healthy controls. Key findings: 43% of tacrolimus-treated patients displayed hypomagnesemia; fractional excretion of magnesium 7.42% vs. 1.88% in controls (nearly fourfold higher); 24-hour urinary magnesium excretion 112.36 mg/dL vs. 6.7 mg/dL in controls. Tacrolimus trough level was the single best predictor of urinary magnesium loss. Magnesium replacement did not influence fractional excretion or 24-hour urinary excretion, confirming the permanent nature of the wasting mechanism. Source for the 43% incidence and the fractional excretion data cited in the piece.

Chaves, M., et al. “Prevalence, Risk Factors and Potential Protective Strategies for Hypomagnesemia in Kidney Transplant Recipients.” International Journal of Molecular Sciences 26, no. 13 (2025): 6528. https://doi.org/10.3390/ijms26136528.

2025 review and cohort study. Documents TRPM6 downregulation by tacrolimus as the primary renal wasting mechanism; confirms dose-dependent effect (patients with hypomagnesemia had significantly higher tacrolimus trough levels: 8.22 vs. 7.68 ng/mL, p=0.03). Also covers sirolimus/mTOR inhibitor effects and the protective role of SGLT2 inhibitors on magnesium homeostasis. Source for the TRPM6 mechanism section.

Proton Pump Inhibitors and Hypomagnesemia in Transplant Recipients

686 stable outpatient kidney transplant recipients, functioning allograft ≥1 year. 56.6% on PPIs. Key findings: PPI use associated with lower plasma magnesium (β: −0.02, P=0.02) and lower 24-hour urinary excretion (β: −0.82, P<0.001). PPI users had more than twice the odds of hypomagnesemia vs. non-users (OR: 2.12; 95% CI 1.43–3.15, P<0.001). Risk was highest at high PPI doses (>20mg omeprazole Eq/day) and was independent of tacrolimus use. Source for the two-front war framing and the OR 2.12 figure in the piece.

Magnesium Supplement Bioavailability — Forms Comparison

Firoz, M., and M. Graber. “Bioavailability of US Commercial Magnesium Preparations.” Magnesium Research 14, no. 4 (2001): 257–262. https://pubmed.ncbi.nlm.nih.gov/11794633/.

Comparative bioavailability study of four commercially available magnesium preparations. Fractional absorption of magnesium oxide was approximately 4%, significantly lower than organic forms. Source for the 4% absorption rate figure cited in the piece and the basis for the magnesium oxide section. Often cited alongside the Shils 1999 data on inorganic vs. organic magnesium salt absorption.

Pelletier-Vicuna, C.M., et al. “Bioavailability of Magnesium Food Supplements: A Systematic Review.” Clinical Nutrition40, no. 6 (2021): 3605–3614. https://www.sciencedirect.com/science/article/abs/pii/S0899900721001568.

Systematic review of magnesium supplement bioavailability. Covers the two absorption mechanisms (active TRPM6-mediated transport at lower doses; passive paracellular diffusion at higher doses), the dipeptide transporter (PEPT1) pathway for amino acid chelates including magnesium glycinate, and the dose-dependent nature of the saturation ceiling. Source for the absorption mechanism section and the glycinate PEPT1 pathway description.

Mycophenolate Interaction with Magnesium-Containing Antacids

Novartis Pharmaceuticals. “Myfortic (Mycophenolate Sodium)—U.S. Prescribing Information.” FDA.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021850s031lbl.pdf.

FDA-approved prescribing label. Documents the pharmacokinetic interaction between magnesium-aluminum-containing antacids and mycophenolate sodium (Myfortic): concurrent administration in 12 stable renal transplant patients reduced mean Cmax by 25% and AUC by 37%. Recommends administration separation. Source for the 25%/37% reduction figures cited in the interactions section. The same interaction is documented in the CellCept (mycophenolate mofetil) prescribing information with similar magnitude.

Outstanding Verification Note

• ThyroMag trial (2025), cited in the levothyroxine interaction paragraph — the first study to examine magnesium-levothyroxine interaction specifically, prior guidance having been extrapolated from calcium and iron data. A verified PubMed citation was not located during the research pass for this piece. Confirm the trial name, journal, and authors before the piece goes to press or the interaction paragraph is updated to remove the specific trial reference.

All About Tacrolimus

FDA Prescribing Information

Astellas Pharma US, Inc. “PROGRAF (tacrolimus) Prescribing Information.” DailyMed, National Library of Medicine. Last revised August 2023. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f667de1-9dfa-4bd6-8ba0-15ee2d78873b.

Primary source for all adverse reaction frequencies cited in the piece: tremor (48–56%), insomnia (32–64%), hypomagnesemia (16–48%), and hyperglycemia (listed among the most common adverse reactions at ≥15%). Also the source for the dosing table, therapeutic drug monitoring guidance, CYP3A4 drug interaction warnings, and the contraindication for concomitant use with sirolimus in heart transplant. Cited three times in the article: in the opening FDA approval reference, the “Too High” section, and the Side Effects introduction.

Fat Content and Tacrolimus Absorption

Bekersky, Ivan, Robert M. Fielding, David E. Dressler, John W. Lee, David N. Buell, and Leslie Z. Benet. “Effect of Low‐ and High‐Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects.” Journal of Clinical Pharmacology 41, no. 2 (2001): 176–182. https://pubmed.ncbi.nlm.nih.gov/11210398/.

Three-period crossover study in 15 healthy male volunteers. Established that high-fat meals reduce tacrolimus AUC by approximately 35–40% and delay Tmax from 1.37 hours (fasted) to 6.47 hours (high-fat). Low-fat meals produced intermediate reduction. Primary citation for the fat-content absorption section and the consistency-over-perfection principle in dosing.

Grapefruit and CYP3A4 Inhibition

Bailey, David G., George Dresser, and J. Malcolm O. Arnold. “Grapefruit–Medication Interactions: Forbidden Fruit or Avoidable Consequences?” Clinical Pharmacology & Therapeutics (2013). https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2968.

Cited for the mechanism and duration of grapefruit’s CYP3A4 inhibition via furanocoumarins, and specifically the finding that a single glass of grapefruit juice can impair tacrolimus metabolism for up to 72 hours. Supports the absolute contraindication on grapefruit in the drug interaction section.

Tacrolimus-Induced Alopecia

Tricot, Leila, Céleste Lebbé, Evangéline Pillebout, Frank Martinez, Christophe Legendre, and Eric Thervet. “Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients.” Transplantation 80, no. 11 (December 15, 2005): 1546–1549. https://pubmed.ncbi.nlm.nih.gov/16371923/.

Retrospective cohort study of 58 simultaneous kidney-pancreas transplant recipients. Clinically significant alopecia in 28.9% of tacrolimus-treated patients versus 0% in cyclosporine-treated patients (P<0.001). Cited for the ~29% incidence figure and the comparative finding against cyclosporine. Noted female predominance (11 of 13 alopecia cases were female). Source for the hair loss paragraph in the Side Effects section.

ISHLT Registry Data — Long-Term Outcomes and Renal Dysfunction

International Society for Heart and Lung Transplantation. “ISHLT Transplant Registry.” ISHLT Registries. https://ishltregistries.org/registries/slides.asp.

Cited for the registry-level finding that chronic renal dysfunction is among the leading long-term complications after heart transplantation, and that tacrolimus is the primary pharmacologic driver. Supports the nephrotoxicity discussion in the Side Effects section and the Narrow Road closing argument. Registry data are updated annually; readers should consult the current slides for the most recent figures.

All About Prednisone

Prednisone — Drug Labeling

Hikma Pharmaceuticals USA Inc. “PredniSONE Tablets, Oral Solution, and Intensol—Prescribing Information.” DailyMed. National Institutes of Health. Revised February 2024. DailyMed / NIH.

FDA-approved prescribing label accessed via DailyMed (NIH’s official drug labeling database). Source for mechanism of action (synthetic glucocorticoid, cortisol analog), immunosuppressive and anti-inflammatory properties, sodium retention and fluid accumulation, glucose elevation, and the broad-spectrum immune suppression described in the piece. DailyMed URLs are stable; FDA direct links are not.

Physical Side Effects — Bone Loss, Calcium, and Vitamin D

Mazziotti, Gherardo, et al. “Glucocorticoid-Induced Osteoporosis: An Update.” Nature Reviews Rheumatology 19 (2023): 83–98. PubMed.

Comprehensive 2023 review of glucocorticoid-induced bone loss. Covers the mechanism by which corticosteroids impair calcium absorption and interfere with vitamin D metabolism, producing osteoblastic suppression and increased bone resorption. Source for the bone density section and the rationale for calcium and vitamin D supplementation in recipients on long-term corticosteroid therapy. Also cited in The Immunosuppression Regimen and The Supporting Cast.

Homik, Joanne, et al. “Calcium and Vitamin D for Corticosteroid-Induced Osteoporosis.” Cochrane Database of Systematic Reviews 2 (1998): CD000952. Cochrane.

Cochrane meta-analysis of five trials (742 patients). Found clinically and statistically significant prevention of bone loss at lumbar spine and forearm with calcium and vitamin D in corticosteroid-treated patients. Concludes that all patients beginning corticosteroid therapy should receive prophylactic calcium and vitamin D. Source for the supplementation-as-standard claim in the piece.

Emotional and Psychological Side Effects

American Journal of Psychiatry review. Covers the full range of neuropsychiatric adverse effects of glucocorticoids including mood changes, depression, anxiety, mania, delirium, and cognitive impairment. Documents severe neuropsychiatric consequences occurring in 15.7 per 100 person-years for all glucocorticoid courses, and 52.5% of patients developing one or more mood-related conditions in a case series at a mean dose of 42mg/day for three months. Also documents hippocampal volume reduction and right amygdala atrophy correlated with duration of prednisone treatment. Source for the neuropsychiatric mechanism section and the blood-brain barrier discussion.

Systematic review and meta-analysis. The most substantial associations with glucocorticoid use were depression and mania. Covers HPA axis dysregulation, neurotransmitter alterations, and the range of neuropsychiatric outcomes. Source for the neuropsychiatric burden described in the piece and the mechanism-level explanation of emotional lability.

West, S., and C. Kenedi. “Strategies to Prevent the Neuropsychiatric Side-Effects of Corticosteroids: A Case Report and Review of the Literature.” Current Opinion in Organ Transplantation 19, no. 2 (2014): 201–208. LWW Journals.

Transplant-specific review of neuropsychiatric complications of corticosteroids. Key finding: the incidence of neuropsychiatric complications rises rapidly once the daily dose of prednisone exceeds 40mg. Directly relevant to the transplant context and the high-dose induction doses described in the piece. Also documents that all patients receiving corticosteroids and their caregivers should be warned about potential neuropsychiatric complications—the central argument of the piece’s emotional and caregiver sections.

Nanthakumar, Seyon, et al. “Corticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications.” Diseases 12, no. 12 (2024): 300. PubMed Central.

Comprehensive 2024 review. Covers corticosteroid effects on the HPA axis, glucocorticoid receptor activity in the hippocampus, amygdala, and prefrontal cortex, neurotransmitter dysregulation (dopamine, serotonin, glutamate), and structural brain changes. Mechanism-level source for the piece’s description of prednisone crossing the blood-brain barrier and acting on glucocorticoid receptors in the regions governing emotional regulation and executive function. Also cited in When the Dam Leaks.

Blood Sugar and Diabetogenic Effects

Hauner, Hans. “Diabetogenic Mechanisms of Immunosuppressive Agents.” Transplantation Reviews (2006). PubMed Central.

Already cited in The Long Game and other H&M pieces. Used here for the compound diabetogenic burden described in the piece: tacrolimus suppresses insulin secretion, sirolimus causes insulin resistance, and prednisone contributes gluconeogenesis stimulation and peripheral insulin resistance—three independent mechanisms acting simultaneously. Source for the multifactorial framing of post-transplant blood sugar elevation.

Outstanding Verification Note

• Steroid psychosis incidence at very high doses — the piece notes this is rare but documented, and that it resolves with dose reduction. The Boston Collaborative Drug Surveillance Program data (1972) cited in Brown & Gelaye 2014 provides the foundational dose-response data: 1.3% at under 40mg/day, 4.6% at 41–80mg/day, 18.6% above 80mg/day. The West & Kenedi 2014 transplant-specific paper confirms the >40mg threshold. These two sources together cover the dose-response claim without requiring a separate citation for the original 1972 BCDSP paper.

Glucose Management After Transplant

[1] Diker Cohen, Talia, et al. “Endocrine Effects of Long-Term Calcineurin Inhibitor Use in Solid Organ Transplant Recipients.” European Journal of Endocrinology 193, no. 3 (2025): R1–R16. https://doi.org/10.1093/ejendo/lvaf182

[2] Hauner, Hans. “Diabetogenic Mechanisms of Immunosuppressive Agents.” Transplantation Reviews (2006). https://pmc.ncbi.nlm.nih.gov/articles/PMC4838515/

[3] Mazzone, et al. “Post-Heart Transplant Diabetes Mellitus: Incidence, Prevalence and Outcomes.” Journal of Heart and Lung Transplantation (2020). https://www.sciencedirect.com/science/article/abs/pii/S1053249820306446

[4] Bouchard-Mercier, et al. “Temporal Changes on the Risks and Complications of Posttransplantation Diabetes Mellitus Following Cardiac Transplantation.” PubMed Central (2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250037/

[5] Astellas Pharma US. “Prograf (Tacrolimus)—Prescribing Information.” DailyMed / NIH. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a9767de-1540-4a40-ae2d-81ea5e0d4be5

[6] Hathout, et al. “Posttransplant Diabetes Mellitus in Pediatric Thoracic Organ Recipients Receiving Tacrolimus-Based Immunosuppression.” Transplantation (2001). https://pubmed.ncbi.nlm.nih.gov/11213069/

[7] Hecking, et al. “Management of Post-Transplant Diabetes: Immunosuppression, Early Prevention, and Novel Antidiabetics.” Transplant International (2021). https://onlinelibrary.wiley.com/doi/10.1111/tri.13783

[8] Kittleson, et al. “Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac Allograft Vasculopathy.” Journal of Heart and Lung Transplantation (2011). https://www.jhltonline.org/article/S1053-2498(11)00021-0/abstract

[9] Kaplan, et al. “Strategies for the Management of Adverse Events Associated with mTOR Inhibitors.” Transplantation Reviews (2014). https://www.sciencedirect.com/science/article/pii/S0955470X14000238

[10] Nakashima, et al. “A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of GLP-1 Receptor Agonists.” Drug Design, Development and Therapy (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12052016/

[11] González-Molina, et al. “Use of GLP-1 Type 1 Receptor Agonists in Kidney Transplant Recipients.” Nefrología(2024). https://www.revistanefrologia.com/en-use-glucagon-like-peptide-type-1-articulo-S2013251424002062

[12] McMurray, et al. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.” The Lancet (2020). https://www.thelancet.com/article/S0140-6736(20)31824-9/fulltext

[13] Mitten, et al. “Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.” AACE Clinical Case Reports (2021). https://pubmed.ncbi.nlm.nih.gov/33851013/

[14] Blau, et al. “Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.” New England Journal of Medicine(2017). https://www.nejm.org/doi/full/10.1056/NEJMc1701990

[15] Battelino, Tadej, et al. “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.” Diabetes Care 42, no. 8 (2019): 1593–1603. https://diabetesjournals.org/care/article/42/8/1593/36184/

[16] Packer, Milton, et al. “Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.” New England Journal of Medicine 383 (2020): 1413–1424. https://www.nejm.org/doi/full/10.1056/NEJMoa2022190

[17] McMurray, John J. V., et al. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.” New England Journal of Medicine 381 (2019): 1995–2008. https://www.nejm.org/doi/full/10.1056/NEJMoa1911303

A Tea By Any Other Name

Chicago Manual of Style format. Listed in order of first appearance in the article. Four entries (marked with an asterisk) support claims currently stated in the article’s prose without an inline hyperlink and should be linked inline to match house style.

Opening

*Birdwell, Kelly A., Bruce Decker, James M. Barbarino, et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing” Clinical Pharmacology & Therapeutics, July 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470690/ Primary pharmacogenetic source establishing CYP3A5 genotype as a major determinant of interpatient tacrolimus dosing variability. Supports the opening’s broadened explanation of why two patients on identical doses can have very different blood levels.

True Tea, One at a Time

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. “Green Tea” National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH), Updated 2020. https://www.ncbi.nlm.nih.gov/books/NBK547925/ Authoritative source distinguishing the well-documented hepatotoxicity risk of concentrated green tea extracts from the much rarer, idiosyncratic risk associated with brewed tea and infusions.

Vischini, Gisella, Pasquale Niscola, Ada Stefoni, and Fabio Farneti. “Increased Plasma Levels of Tacrolimus After Ingestion of Green Tea” American Journal of Kidney Diseases, August 2011. https://pubmed.ncbi.nlm.nih.gov/21787983/ Case report of a kidney transplant recipient, genotyped as a CYP3A4 “poor metabolizer,” whose tacrolimus levels rose after green tea ingestion and normalized on discontinuation. The direct clinical evidence behind the green tea/tacrolimus caution; a single case, not a population finding.

Albassam, Ahmed A., and John S. Markowitz. “An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis)” Planta Medica, 2017. https://pubmed.ncbi.nlm.nih.gov/28118673/ Review finding strong in-vitro evidence for green tea catechin effects on CYP3A4 and P-glycoprotein, but a considerably weaker and more mixed clinical picture. Used to calibrate the green tea section’s “worth flagging, not settled” framing.

Meyer, Bailey R., Haley M. White, Jared D. McCormack, and Emily D. Niemeyer. “Catechin Composition, Phenolic Content, and Antioxidant Properties of Commercially-Available Bagged, Gunpowder, and Matcha Green Teas” Plant Foods for Human Nutrition, December 2023. https://pubmed.ncbi.nlm.nih.gov/37923855/ Peer-reviewed laboratory comparison finding matcha and quality bagged/gunpowder green teas in the same general EGCG range per gram, with some conventional teas testing higher. Primary source correcting the widely misquoted “137x” matcha marketing claim.

The Citrus-Adjacent Trap

Pharmacy Times editorial staff. “How Well Do You Know the Grapefruit Drug Interaction?” Pharmacy Times, 2024. https://www.pharmacytimes.com/view/how-well-do-you-know-the-grapefruit-drug-interactionSource for the bergamottin/furanocoumarin mechanism shared by bergamot oil and grapefruit, and for Seville orange peel as a separate source of related compounds distinct from bergamot oil itself.

Miedziaszczyk, Milosz, et al. “Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food” Pharmaceutics, October 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611668/ Review identifying grapefruit, pomelo, clementine, pomegranate, ginger, and turmeric as documented or plausible CYP3A4 inhibitors affecting tacrolimus levels. Primary source for the grapefruit- and pomelo-tea caution.

Egashira, Kunihiro, Fumihiro Fukuda, Tomoyuki Ohta, et al. “Pomelo-Induced Increase in the Blood Level of Tacrolimus in a Renal Transplant Patient” Transplantation, April 2003. https://pubmed.ncbi.nlm.nih.gov/12698101/ Case report of a renal transplant recipient whose tacrolimus level rose sharply after eating under 100 grams of pomelo. Direct clinical citation for the pomelo caution, distinct from the general grapefruit literature.

Herbal Tisanes, Individually

Beppu, Noriko, Takehiko Mori, Jun Kato, et al. “Drug-Herbal Interaction Between Tacrolimus and Rooibos Tea in a Recipient of Allogeneic Hematopoietic Stem Cell Transplantation” International Journal of Hematology-Oncology and Stem Cell Research / Hematopoietic Cell Transplantation, 2013. https://www.jstage.jst.go.jp/article/hct/2/4/2_109/_article Case report of an allogeneic HSCT recipient whose heavy rooibos consumption (>2 L/day) reduced tacrolimus concentration and resulted in GVHD. The article’s central citation for the dose/moderation argument, cited via the MSKCC summary below.

Memorial Sloan Kettering Cancer Center, Integrative Medicine. “Rooibos Tea” MSKCC About Herbs, Botanicals & Other Products database, Accessed 2026. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/rooibos-tea Secondary summary of the Beppu et al. rooibos/tacrolimus case, used as the accessible citation point in the article.

Drugs.com Interactions Checker. “Eliquis and Ginger Interactions” Drugs.com (professional interaction database), Accessed 2026. https://www.drugs.com/drug-interactions/eliquis-with-ginger-3438-16026-1173-0.html?professional=1 Documents a moderate-severity interaction classification between apixaban and ginger, citing published pharmacology literature (Vaes & Chyka 2000; Kruth et al. 2004; Jiang et al. 2005), while noting the underlying human evidence for a platelet effect is mixed.

Hilepo, J.N., or study authors as cited. “Warfarin Interaction with Matricaria chamomilla (Chamomile)” Journal of Herbal Pharmacotherapy / case literature, 2006. https://www.researchgate.net/publication/7145155_Warfarin_interaction_with_Matricaria_chamomillaCase report of a 70-year-old woman on warfarin hospitalized with internal hemorrhage after using chamomile tea and lotion together. Primary case citation for the chamomile/anticoagulant caution.

Tan, Charlotte S. S., et al. “Warfarin and Food, Herbal or Dietary Supplement Interactions: A Systematic Review” British Journal of Clinical Pharmacology, July 2021. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14404 Systematic review listing chamomile tea and ginger, among other herbs, as associated with documented bleeding events specifically in patients on warfarin. Used to calibrate the chamomile and ginger cautions to the actual (warfarin-based, not apixaban-based) evidence.

Sabbadin, Chiara, Elisa Bordin, Nicoletta Sonino, and Marco Boscaro. “Licorice: From Pseudohyperaldosteronism to Therapeutic Uses” Frontiers in Endocrinology, 2019. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00484/full Primary source for the glycyrrhizin/pseudohyperaldosteronism mechanism underlying licorice root’s effect on blood pressure and potassium, independent of the CYP3A4 pathway discussed elsewhere in the piece.

*Caparros-Lefebvre, D., and A. Elbaz, for the Caribbean Parkinsonism Study Group. “Possible Relation of Atypical Parkinsonism in the French West Indies with Consumption of Tropical Plants: A Case-Control Study” The Lancet, July 1999. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)10166-6/fulltext Foundational case-control study investigating consumption of both Annonaceae herbal tea and fruit/juice together in relation to atypical parkinsonism in Guadeloupe. Primary source for the soursop section’s correction that the epidemiological signal is not confined to leaf tea alone.

Gardenia.net editorial staff. “Soursop (Annona muricata): Health Benefits, Uses, Growing Tips” Gardenia.net, 2026. https://www.gardenia.net/plant/annona-muricata-soursop General reference summarizing annonacin’s presence in soursop fruit, seeds, and leaves, and its association with neurotoxicity at high, sustained intake.

People’s Pharmacy editorial staff. “Hibiscus Tea Provides Amazing Blood Pressure Control” The People’s Pharmacy, 2026. https://www.peoplespharmacy.com/articles/hibiscus-tea-provides-amazing-blood-pressure-control General summary of human trial evidence for hibiscus’s blood-pressure-lowering effect, including trials comparing hibiscus to ACE-inhibitor medications, and citing preliminary animal data on a hydrochlorothiazide interaction.

PeaceHealth Health Information Library. “Hydrochlorothiazide” PeaceHealth, Accessed 2026. https://www.peacehealth.org/medical-topics/id/hn-10000534 Source for the animal-study evidence (rats and rabbits) that hibiscus extract can increase hydrochlorothiazide blood levels and slow its clearance. Explicitly labeled as preliminary, non-human data in the article.

National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health. “Echinacea: Usefulness and Safety” NCCIH, Accessed 2026. https://www.nccih.nih.gov/health/echinacea Authoritative source characterizing the echinacea/immunosuppressant interaction as theoretical rather than documented in humans. Used to calibrate the echinacea caution precisely to the evidence.

*Ruschitzka, F., P. J. Meier, M. Turina, T. F. Lüscher, and G. Noll. “Acute Heart Transplant Rejection Due to Saint John’s Wort” The Lancet, February 2000. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)02059-4/fulltext Case report of acute heart transplant rejection attributed to a drop in cyclosporine levels caused by St. John’s wort. One of the primary rejection-case citations distinguishing the cyclosporine evidence from the tacrolimus dose-adjustment evidence.

*Barone, Gary W., Bruce D. Gurley, Barbara L. Ketel, Michael L. Lightfoot, and Steve R. Abul-Ezz. “Drug Interaction Between St. John’s Wort and Cyclosporine” Annals of Pharmacotherapy, September 2000. https://pubmed.ncbi.nlm.nih.gov/10981246/ Case report of a kidney/pancreas transplant recipient whose subtherapeutic cyclosporine levels from St. John’s wort use were associated with organ rejection. Supports the cyclosporine-specific rejection language in the St. John’s wort section.

*Hebert, Mary F., et al., or study authors as cited. “Effects of St. John’s Wort (Hypericum perforatum) on Tacrolimus Pharmacokinetics in Healthy Volunteers” Journal of Clinical Pharmacology / transplant pharmacokinetics literature, 2004. https://www.researchgate.net/publication/10855059_Impact_of_St_John%27s_wort_treatment_on_the_pharmacokinetics_of_tacrolimus_and_mycophenolic_acid_in_renal_transplant_patientsStudy documenting markedly reduced tacrolimus exposure in transplant recipients taking St. John’s wort, requiring significant dose increases. Supports the tacrolimus-specific half of the St. John’s wort distinction (reduced exposure, not itself the rejection evidence).

What’s Hiding in the Blend

*U.S. Food and Drug Administration. “Dietary Supplements” FDA.gov, Accessed 2026. https://www.fda.gov/food/dietary-supplements Primary regulatory source confirming dietary supplements are regulated under the Dietary Supplement Health and Education Act (DSHEA), distinct from conventional foods and drugs, and generally reach market without FDA premarket approval for safety or effectiveness.

A Word on Mushroom Coffee

News-Medical.net editorial staff. “The Truth About Mushroom Coffee: Benefits vs. Hype” News-Medical.net, February 2025. https://www.news-medical.net/health/The-Truth-About-Mushroom-Coffee-Benefits-vs-Hype.aspx General summary of the polysaccharide and beta-glucan content of reishi and chaga mushrooms and their studied immunomodulatory effects, used to support the mushroom coffee caution without overstating a settled clinical interaction.

What Your Ring Actually Knows

Heart Rate Variability and the Denervated Heart

Sanders, Ward J., et al. “The 24-Hour Heart Rate Behavior in Long-Term Survivors of Cardiac Transplantation” American Journal of Cardiology, April 1988. https://pubmed.ncbi.nlm.nih.gov/3281427/Foundational study establishing the magnitude of heart rate variability reduction in denervated transplanted hearts (60 ms) versus normal hearts (151 ms). Supports the HRV denervation discussion in the “Heart Rate Variability and the Denervated Heart” section.

Awad, Morcos, Lawrence S. C. Czer, Margaret Hou, Sarah S. Golshani, Michael Goltche, Michele De Robertis, Michelle Kittleson, Jignesh Patel, Babak Azarbal, Evan Kransdorf, Fardad Esmailian, Alfredo Trento, and Jon A. Kobashigawa. “Early Denervation and Later Reinnervation of the Heart Following Cardiac Transplantation: A Review” Journal of the American Heart Association, November 2016. https://www.ahajournals.org/doi/10.1161/JAHA.116.004070 Comprehensive review confirming reduced heart rate variability and elevated resting heart rate as consistent findings across the denervation literature, and identifying elevated resting heart rate at one year post-transplant as an independent predictor of mortality. Supports both the HRV and resting heart rate discussion.

Journal of Heart and Lung Transplantation editorial staff. “You’ve Got Some Nerve (After Heart Transplantation)” Journal of Heart and Lung Transplantation, 2022. https://www.jhltonline.org/article/S1053-2498(22)01908-8/abstract States plainly that denervated hearts exhibit higher resting heart rate, reduced HRV, and blunted response to cholinergic medications. Used as the specialty-journal confirmation of the denervation thesis.

Healio Cardiology staff. “Pharmacotherapy Considerations After Heart Transplant: What General Cardiologists Should Know” Healio, November 8, 2017. https://www.healio.com/news/cardiology/20171106/pharmacotherapy-considerations-after-heart-transplant-what-general-cardiologists-should-know Cites the 90–115 bpm resting heart rate range as characteristic of the denervated transplanted heart. Supports the resting heart rate range discussion.

Blood Pressure Estimation

APL Bioengineering editorial staff. “A Review: Blood Pressure Monitoring Based on PPG and Circadian Rhythm” APL Bioengineering, July 2024. https://pubs.aip.org/aip/apb/article/8/3/031501/3304394/A-review-Blood-pressure-monitoring-based-on-PPG Explains the pulse arrival time / pulse transit time mechanism by which wearables estimate blood pressure from PPG and ECG signal timing. Supports the mechanism explanation in “Blood Pressure: An Estimate of an Estimate.”

American Heart Association Newsroom. “Cuffless Blood Pressure Technologies in Wearable Devices Show Promise to Transform Care” American Heart Association, December 2025. https://newsroom.heart.org/news/cuffless-blood-pressure-technologies-in-wearable-devices-show-promise-to-transform-care AHA scientific statement recommending against clinical use of cuffless blood pressure devices for diagnosis, tracking, or treatment. Primary source for the AHA position stated in the article.

EurekAlert! / American Heart Association. “Cuffless Blood Pressure Devices Show Great Promise as Alternatives to Traditional Arm-Cuff Monitors” EurekAlert!, December 2025. https://www.eurekalert.org/news-releases/1109402 Confirms the 2025 AHA/ACC High Blood Pressure Guideline recommendation against cuffless BP devices for diagnosis or treatment. Supports the guideline reference.

Sleep Staging

Ubie Doctor’s Note editorial staff. “Sleep Trackers vs. Polysomnography: How Accurately Do Wearables Measure Your Sleep Stages?” Ubie, July 2026. https://ubiehealth.com/doctors-note/sleep-tracker-vs-polysomnography-accuracy-stage-4762q2 Summarizes accuracy literature: 85–95% sensitivity for sleep/wake detection, 60–85% accuracy for stage classification against polysomnography. Primary source for the general accuracy figures cited in “Sleep Stages Without an EEG.” Cites De Zambotti et al., Sleep Medicine Reviews, 2023, and Kitzman et al., Sleep, 2023, as underlying sources.

MDPI Sensors editorial staff. “Accuracy of Three Commercial Wearable Devices for Sleep Tracking in Healthy Adults” Sensors, October 2024. https://www.mdpi.com/1424-8220/24/20/6532 Head-to-head validation study of Oura Ring Gen3, Fitbit Sense 2, and Apple Watch Series 8 against polysomnography. Source for the device-specific sensitivity range (50–86%) cited in the sleep staging section.

medRxiv preprint authors. “Electrodermal Activity as a Critical Modality for Wearable Sleep Monitoring: A Comprehensive Systematic Review from Fundamental Physiology to Clinical Translation.” medRxiv, November 2025. https://www.medrxiv.org/content/10.1101/2025.11.14.25340258.full.pdf Source for the REM sleep underestimation figure (50–70%, meta-analysis of 798 patients across 24 studies) referenced and inline-linked in the article.

Sleep Apnea

Sleeplay editorial staff. “Best Sleep Trackers for Sleep Apnea 2026: Apple, Oura, Fitbit” Sleeplay, 2026. https://sleeplay.com/blogs/news/best-sleep-trackers-wearables-sleep-apnea Identifies the specific FDA-cleared devices for sleep apnea notification (Apple Watch Series 9+, Samsung Galaxy Watch 7/8/Ultra, Withings Sleep Analyzer) and confirms no consumer wearable is cleared to diagnose sleep apnea. Primary source for the FDA-cleared device list and the screening-versus-diagnosis distinction.

Single-Lead ECG

Seshadri, Deepak R., et al. “Accuracy and Clinical Relevance of the Single-Lead Apple Watch Electrocardiogram to Identify Atrial Fibrillation” Cardiovascular Digital Health Journal, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795256/ Independent study of post–cardiac surgery patients finding 41% sensitivity and 31% inconclusive rate for Apple Watch single-lead ECG against hospital telemetry — notably lower than manufacturer validation figures. Directly relevant to a post-surgical cardiac population; supports the ECG limitations discussion.

Case report authors. “Utility and Limitations of Smartwatch Electrocardiogram Monitoring in a Patient with Idiopathic Monomorphic Ventricular Tachycardia” HeartRhythm Case Reports, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184831/ Case report demonstrating that serious arrhythmias can appear disorganized on smartwatch ECG tracings, risking misinterpretation. Concludes smartwatch ECG should serve as an early-detection tool, not a replacement for 12-lead diagnostics. Supports the concluding caution in the ECG section.

FDA Clearance and “Medical Grade”

CuriousCatalyst. ““Medical-Grade” Is a Marketing Claim. Here’s What FDA Clearance Actually Means for Your Wearable.” Medium, April 2026. https://medium.com/@CuriousCatalyst/medical-grade-is-a-marketing-claim-heres-what-fda-clearance-actually-means-for-your-wearable-498718d806b5Summarizes the January 2026 FDA wellness-device guidance, including FDA Commissioner Makary’s public statements distinguishing general wellness claims from medical-grade claims, and the Whoop blood pressure warning letter. Primary source for the “FDA Cleared” section’s regulatory explanation.

Blood Glucose

AARP Health staff. “Don’t Use Your Smartwatch or Smart Ring to Measure Blood Glucose Levels, FDA Says” AARP, February 2024. https://www.aarp.org/health/conditions-treatments/smartwatches-smartrings-glucose-monitoring-warning/ Reports the FDA’s direct statement that it has not authorized, cleared, or approved any smartwatch or ring for independent blood glucose measurement, and confirms major manufacturers (Apple, Fitbit, Oura, Samsung) do not make this claim. Primary source for the glucose non-claim section.

Fierce Biotech staff. “FDA Warns on Smartwatches Touting Noninvasive Glucose Sensors” Fierce Biotech, February 2024. https://www.fiercebiotech.com/medtech/fda-reminds-world-it-has-yet-ok-smartwatches-noninvasive-glucose-monitoring Confirms the FDA safety communication urging consumers not to purchase, and to stop using, unauthorized glucose-monitoring smartwatches and rings. Supports the FDA warning reference.

U.S. Food and Drug Administration. “Home Healthcare Medical Devices: Blood Glucose Meters — Getting the Most Out of Your Meter” FDA.gov, Accessed 2026. https://www.fda.gov/medical-devices/home-health-and-consumer-devices/home-healthcare-medical-devices-blood-glucose-meters-getting-most-out-your-meter Direct FDA statement that home blood glucose meter technology is not as accurate as laboratory or clinical testing. Primary source for the finger-stick accuracy limitation.

Katz, Laurence B., Lorna Stewart, Danielle King, and Hilary Cameron. “Meeting the New FDA Standard for Accuracy of Self-Monitoring Blood Glucose Test Systems Intended for Home Use by Lay Users.” Journal of Diabetes Science and Technology, February 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7753858/ Underlying source for the finger-stick meter accuracy standard; supports the “have their own allowable error” claim, inline-linked in the article.

TCOYD (Taking Control of Your Diabetes) editorial staff. “CGM vs Fingerstick Accuracy: How Close Should the Values Be?” TCOYD, July 2025 (updated). https://tcoyd.org/2022/02/cgm-values-vs-finger-sticks-how-close-should-the-values-be/ Underlying source for CGM interstitial-fluid measurement and CGM-to-fingerstick tolerance; supports the “measure glucose in interstitial fluid” claim, inline-linked in the article. Reviewed by Dr. Steven Edelman.

Device Specifications

TechRadar staff. “RingConn Gen 3 Review: Refining an Already Solid Formula to Deliver a Reliable, Discreet Health Tracker” TechRadar, 2026. https://www.techradar.com/health-fitness/ringconn-gen-3-reviewIndependent hands-on testing confirming RingConn Gen 3 battery life (11–14 days claimed, ~12.5 days measured). Supports the RingConn battery life claim in the device section.

Support.ouraring.com. “Oura Ring 5” Oura, 2026. https://support.ouraring.com/hc/articles/50997181300243-Oura-Ring-5 Manufacturer specifications confirming Oura Ring 5’s 6–9 day battery life and 40% size reduction versus Gen 4. Supports the Oura Gen 5 device writeup.

TechCrunch staff. “Oura Ring 5 Review: Thinner, Lighter, Better” TechCrunch, June 2026. https://techcrunch.com/2026/06/04/oura-ring-5-review-thinner-lighter-better/ Independent review confirming the size and comfort improvement over prior Oura generations. Supports the “small tire” comparison and slimmer-profile claim.

Wareable staff. “Hume Band 2.0 Review: Is It Worth Upgrading in 2026?” Wareable, June 2026. https://www.wareable.com/health-tech/hume-band-2-0-review Independent review confirming Hume Band v2’s battery life improvement (up to 14 days) over v1 (5–7 days). Supports the Hume Band v1-to-v2 comparison in the device section.

Android Authority staff. “Google Pixel Watch 4 Review: The Wear OS Watch I’ve Been Waiting For” Android Authority, October 2025. https://www.androidauthority.com/google-pixel-watch-4-review-3604086/Independent review confirming real-world Pixel Watch 4 battery life of a day and a half to two days, against Google’s 30–40 hour claim. Supports the Pixel Watch 4 battery life figure.

While You Were Sleeping

What Sleep Apnea Does to the Heart

MDPI Journal of Cardiovascular Development and Disease editorial staff. “Impact of Obstructive Sleep Apnea and Sympathetic Nervous System on Cardiac Health: A Comprehensive Review” Journal of Cardiovascular Development and Disease, June 2024. https://www.mdpi.com/2308-3425/11/7/204Comprehensive review establishing the association between untreated OSA and hypertension, arrhythmias, myocardial infarction, and heart failure via sympathetic activation. Primary source for the cardiovascular consequences summarized in the opening section.

PMC editorial compilation. “Impact of Obstructive Sleep Apnea and Sympathetic Nervous System on Cardiac Health: A Comprehensive Review” PMC (National Library of Medicine), 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277108/ Source for the specific association between OSA, recurrent hypoxia, sympathetic activation, and atrial fibrillation risk. Supports the arrhythmia-specific claim for the cardiac readership.

PubMed / Circulation editorial listing. “Obstructive Sleep Apnea and Heart Failure: Pathophysiologic and Therapeutic Implications” Circulation, January 2011. https://pubmed.ncbi.nlm.nih.gov/21211682/ Source for the bidirectional OSA–heart failure relationship: intermittent hypoxia, oxidative stress, inflammation, and sympathetic overactivation contributing to heart failure development and progression, and moderate-to-severe OSA associated with worse HF outcomes.

After the Transplant

Javaheri, Shahrokh, William T. Abraham, Christopher Brown, Hiroshi Nishiyama, Robert Giesting, and Larry E. Wagoner. “Prevalence of Obstructive Sleep Apnoea and Periodic Limb Movement in 45 Subjects with Heart Transplantation” European Heart Journal, February 2004. https://pubmed.ncbi.nlm.nih.gov/14972428/?dopt=Abstract First systematic polysomnography evaluation of sleep disorders in cardiac transplant recipients; found 36% prevalence of moderate-to-severe obstructive sleep apnea. Primary source for the transplant-prevalence claim.

Study authors (single-center retrospective cohort). “Sleep Apnea in Heart Transplant Recipients: Type, Symptoms, Risk Factors, and Response to Nasal Continuous Positive Airway Pressure” Journal of Heart and Lung Transplantation, April 2000. https://www.sciencedirect.com/science/article/abs/pii/S105324980000067X Single-center study of 146 orthotopic heart transplant recipients finding OSA in more than one-third of subjects. Also the source of the weight-gain finding: 16 of 17 (94%) recipients referred for suspected sleep apnea had gained a mean of 10.4 kg post-transplant. Cited twice in the article for these two separate findings.

Study authors. “The Effect of Obstructive Sleep Apnea on 3-Year Outcomes in Patients Who Underwent Orthotopic Heart Transplantation” American Journal of Cardiology, 2019. https://www.sciencedirect.com/science/article/abs/pii/S000291491930400X Retrospective review of 146 OHT recipients finding untreated OSA at time of transplant associated with three times the risk of late graft dysfunction versus treated/no OSA (hazard ratio 3.2, 95% CI 1.3–7.9, p=0.01). The single strongest clinical-relevance finding in the article’s transplant section.

Miura, Kie, et al. “Weight Gain After Heart Transplantation in Adults: Systematic Review and Meta-Analysis” Journal of Heart and Lung Transplantation, September 2021. https://pubmed.ncbi.nlm.nih.gov/34560719/ Pooled analysis of ten studies finding average weight gain of 7.1 kg at twelve months post-transplant across all recipients, with U.S. cohorts averaging 10.42 kg — the highest of any region studied. Broadens the single-series weight-gain figure into a general, well-supported finding.

When the Heart Itself Changes the Breathing

ScienceDirect / Revista Portuguesa de Cardiologia editorial compilation. “Cheyne-Stokes Respiration in Patients with Congestive Heart Failure: Causes and Consequences” Revista Portuguesa de Cardiologia, 2005. https://www.sciencedirect.com/science/article/pii/S1807593222030496 Source for the core pathophysiological mechanism of Cheyne-Stokes respiration: hyperventilation and low arterial CO2 dropping below the apneic threshold, associated with sympathetic activation in CHF patients.

PMC editorial compilation. “Severe Sleep Apnea, Cheyne-Stokes Respiration and Desaturation in Patients with Decompensated Heart Failure at High Altitude” PMC (National Library of Medicine), 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6201522/ Source for the prevalence figures: Cheyne-Stokes respiration described in 30 to 50% of patients with stable severe heart failure, and its association with lower ejection fraction and worse functional class.

Study authors. “Influence of Orthotopic Heart Transplantation on Breathing Pattern Disorders in Patients with Dilated Cardiomyopathy” Sleep and Breathing, 2000. https://link.springer.com/article/10.1007/s11325-000-0121-y Direct heart-transplant evidence: polysomnography on 29 patients with Cheyne-Stokes respiration and pretransplant LVEF of 8–19%, repeated 3–9 weeks post-transplant. LVEF rose to a mean of 64%; 23 of 29 patients showed no further periodic breathing. The central citation for the article’s Cheyne-Stokes/transplant argument.

Al-Saleh, S., et al. “Impact of Heart Transplantation on Cheyne-Stokes Respiration in a Child” Case Reports in Pediatrics, 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835643/ Pediatric case report documenting Cheyne-Stokes respiration fully resolving after heart transplantation. Supports the claim that this pattern’s resolution after transplant has been documented in both adult and pediatric recipients.

Apnea, Hypopnea, and Severity

American Association of Sleep Technologists editorial staff. “Obstructive vs. Central Sleep Apnea: Key Differences and Treatment Options” AAST, March 2025. https://aastweb.org/obstructive-vs-central-sleep-apnea-key-differences-and-treatment-options/ Source for the mechanistic distinction between obstructive apnea (effort present, airway blocked) and central apnea (no effort, brain not signaling to breathe).

SleepApnea.org editorial staff. “Hypopnea: Definition, Symptoms, and Causes” SleepApnea.org, January 2026. https://www.sleepapnea.org/hypopnea/ Source for the technical definition of hypopnea (at least 30% airflow reduction for 10+ seconds with oxygen desaturation or arousal) versus full apnea (90%+ reduction).

SleepApnea.org editorial staff. “Central Sleep Apnea: Causes, Symptoms, and Treatment” SleepApnea.org, July 2026. https://www.sleepapnea.org/central-sleep-apnea/ Source for treatment-emergent central sleep apnea (TECSA): occurs in roughly 5–15% of new PAP users, usually self-resolving within weeks to months. Distinguished in the article from the author’s own heart-failure-related central apnea.

remedē System / ZOLL editorial staff. “What Is Central Sleep Apnea (CSA)? Symptoms, Causes, and Treatment Options” remedē System (ZOLL Medical), June 2026. https://remede.zoll.com/what-is-central-sleep-apnea-csa-symptoms-causes-and-treatment-options/ Source for the point that in some treatment-emergent central sleep apnea cases, the cause cannot be identified at all (idiopathic TECSA).

Getting Diagnosed

PMC editorial compilation. “Autonomic Arousal Detection and Cardio-Respiratory Sleep Staging Improve the Accuracy of Home Sleep Apnea Tests” PMC (National Library of Medicine), 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484584/ Source for the AASM’s endorsement of home sleep apnea testing in uncomplicated, high-risk adults, alongside the caveat that mild-to-moderate severity may be underestimated.

Sleep Foundation editorial staff. “At-Home Sleep Study — Are Home Tests a Better Option?” Sleep Foundation, November 2025. https://www.sleepfoundation.org/sleep-studies/at-home-sleep-studySource for the specific mechanism of HSAT underestimation: home tests calculate an hourly event rate that can appear lower than reality because they can’t distinguish sleep from wake as precisely as in-lab polysomnography.

CPAP, APAP, BiPAP

SleepApnea.org editorial staff. “BiPAP vs. CPAP: Differences, Benefits, and Uses” SleepApnea.org, March 2026. https://www.sleepapnea.org/cpap/cpap-vs-bipap/ Source for the basic CPAP mechanism: one continuous fixed pressure throughout the night.

Sleep Doctor editorial staff. “What Is a CPAP Machine? (Difference Between CPAP, APAP, BiPAP and ASV)” SleepDr, June 2026. https://sleepdr.com/the-sleep-blog/what-is-a-cpap-machine-difference-between-cpap-apap-bipap-and-asv Source for the BiPAP mechanism (two fixed pressure levels) and typical clinical indications for moving from CPAP/APAP to BiPAP.

American College of Cardiology editorial staff. “SERVE-HF: Adaptive Servo-Ventilation Therapy to Treat Central Sleep Apnea in Systolic HF Patients” American College of Cardiology, August 2015. https://www.acc.org/latest-in-cardiology/articles/2015/08/30/11/43/serve-hf-adaptive-servo-ventilation-therapy-to-treat-central-sleep-apnea-in-systolic-hf-patients Summary of the SERVE-HF trial results: increased cardiovascular mortality risk with ASV in heart failure patients with reduced ejection fraction and predominant central sleep apnea, using an early-generation device.

American Academy of Sleep Medicine. “Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline” AASM Practice Parameters, 2016.https://aasm.org/resources/practiceparameters/asv.pdf Source for the original standard-level recommendation against ASV in patients with LVEF ≤45% and moderate-or-severe central sleep apnea, issued following SERVE-HF.

Badr, M. Safwan, Rami N. Khayat, Jean S. Allam, et al. “New Guideline Provides Treatment Recommendations for Central Sleep Apnea” American Academy of Sleep Medicine, October 2025. https://aasm.org/new-guideline-provides-treatment-recommendations-for-central-sleep-apnea/ AASM announcement of the 2025 updated central sleep apnea clinical practice guideline (published in the Journal of Clinical Sleep Medicine, 21(12)), replacing the 2016 blanket caution with a conditional recommendation for ASV in HFrEF at experienced centers with close monitoring. The key citation grounding the article’s present-tense treatment of current ASV guidance.

The Wellue O2Ring-S

MedGrade editorial staff. “Wellue O2Ring Review: Medical-Grade Precision for Overnight Oxygen Monitoring” MedGrade, March 2026. https://medgrade.org/reviews/wellue-o2ring-review/ Source for independent clinical validation figures: 87.3% sensitivity and 78.7% specificity for identifying an AHI of 15 or greater, and the FDA submission (K191088) supporting ±2% SpO2 accuracy in the 80–100% range.

Wellue (Viatom Technology) product listing. “Wellue O2Ring-S Oxygen Monitor for Small Fingers” Amazon.com (manufacturer listing), Accessed 2026. https://www.amazon.com/Wellue-O2Ring-S-Vibration-Bluetooth-Rechargeable/dp/B0CKVTYGCW Manufacturer’s own product listing stating the O2Ring-S is not a medical device and is intended for sports and aviation use only, not medical use. Primary source for the regulatory-status claim, verified against the specific -S model rather than the earlier base O2Ring.

Caregivers Corner

A Child’s View

1. Ågren S, Ivarsson B, Rönning H. “The Unsteady Mainstay of the Family: Now Adult Children’s Retrospective View on Social Support in Relation to Their Parent’s Heart Transplantation.” Nursing Research and Practice. 2014;2014:541241. doi:10.1155/2014/541241. https://pmc.ncbi.nlm.nih.gov/articles/PMC4241330/ — The only peer-reviewed study specifically examining adult children’s experiences of social support during a parent’s heart transplantation. Key finding: significant lack of support; information largely absent. Used in opening, Section 4, and Resources.

2. McCarthy C. “How to talk to children about the serious illness of a loved one.” Harvard Health Publishing. January 14, 2020. https://www.health.harvard.edu/blog/how-to-talk-to-children-about-the-serious-illness-of-a-loved-one-2019120218468 — Developmental stage-appropriate communication during parental serious illness. Children imagine things worse than reality when not told the truth; honest communication is protective. Used in Sections 2 and The Pivot.

3. Metzing S, Chikhradze N. “Young carers: growing up with chronic illness in the family—a systematic review 2007–2017.” Journal of Compassionate Health Care. 2017;4:12. doi:10.1186/s40639-017-0041-3. https://link.springer.com/article/10.1186/s40639-017-0041-3 — Systematic review of 25 studies. Young carers conceal relatives’ conditions, limit social experience, prioritize family over own needs. Used in Section 3.

4. Chen CY, Panebianco A. “Physical and psychological conditions of parental chronic illness, parentification and adolescent psychological adjustment.” Psychology & Health. 2020;35(9):1075–1094. doi:10.1080/08870446.2019.1699091. https://www.tandfonline.com/doi/full/10.1080/08870446.2019.1699091 — Ill parent’s emotional wellbeing—not physical limitations—directly predicts adolescent distress. Emotional parentification harms adjustment; instrumental parentification alone does not. Used in Sections 3 and The Pivot.

5. Boss P, Couden BA. “Ambiguous loss from chronic physical illness: Clinical interventions with individuals, couples, and families.” Journal of Clinical Psychology. 2002;58(11):1351–1360. doi:10.1002/jclp.10083. https://onlinelibrary.wiley.com/doi/10.1002/jclp.10083 — Ambiguous loss framework applied to chronic illness. Lack of clarity about prognosis creates relationship confusion, preoccupation, or avoidance. Applied to children in households where a parent’s future is perpetually uncertain. Used in Section 4.

6. Kaasbøll J et al. “Parental Chronic Illness, Internalizing Problems in Young Adulthood and the Mediating Role of Adolescent Attachment to Parents.” Frontiers in Psychiatry. 2021;12:807563. doi:10.3389/fpsyt.2021.807563. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.807563/full — Parental chronic illness increases risk for social-emotional and behavioral problems; affective dysregulation, somatic symptoms, shame, guilt, isolation. Used in Sections 2 and 5.

7. Goldenberg E. “Understanding Bowen Family Systems Theory.” Psychology Today. November 13, 2023. https://www.psychologytoday.com/us/blog/your-emotional-meter/202311/understanding-bowen-family-systems-theory — Secondary source for Bowen triangulation concept: when a two-person system experiences excess tension, a third party is drawn in to stabilize anxiety. Used in Section 3.

8. UC Davis Children’s Hospital. “Parenting Through Illness.” Patient Education. https://health.ucdavis.edu/children/patient-education/parenting-through-illness — Developmental stage guidance. Young children understand household changes before understanding illness; magical thinking may lead them to believe they caused it. Used in Section 1.

9. Muylaert CJ et al. “A Scoping Review of the Mental Health Aspects of Parentification.” International Journal of Mental Health Promotion. 2023. https://www.techscience.com/IJMHP/online/detail/24924/pdf — Emotional parentification more harmful than instrumental; ill parent’s emotional state more predictive of adolescent distress than physical illness severity. Used in Section 3.

10. Mazzeschi C et al. “Impact of Parental Cancer on Children: Differences by Child’s Age and Parent’s Disease Stage.” Children. 2024;11(6):687. doi:10.3390/children11060687. https://pmc.ncbi.nlm.nih.gov/articles/PMC11201568/ — Age-based differences in children’s coping with parental serious illness; younger children may have difficulty managing negative emotions; internalizing symptoms vary by developmental stage. Used in Section 1.

11. Sacks D et al. “Experiences of medical traumatic stress in parents of children with medical complexity.” Child: Care, Health and Development. 2022. PMC10087969. https://pmc.ncbi.nlm.nih.gov/articles/PMC10087969/ — Cites Kazak et al. (2006) definition of Pediatric Medical Traumatic Stress (PMTS): psychological and physiological reactions of children and their families to pain, serious illness, medical procedures, and invasive treatment experiences. Responses persist after the acute phase ends. Used in Section 5.

Reflections

Gratitude and Its Complications

No external citations. Gratitude and Its Complications is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

And Yet

No external citations. And Yet is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

Am I Still Me?

Carroll, Robert Todd. “Cellular Memory.” The Skeptic’s Dictionary. Skeptic’s Dictionary.

Cited inline as the authoritative skeptical assessment of the cellular memory hypothesis as “magical thinking dressed in the vocabulary of physics.”

Bhavsar, Sohail, et al. “Personality Changes Following Heart Transplantation.” Transplantology 5, no. 1 (2024). MDPI.

2024 cross-sectional study cited inline: 89% of organ recipients reported personality changes post-surgery, but heart recipients were no more likely to report changes than kidney, liver, or lung recipients. Cited to rebut donor personality transfer claims on evidential grounds.

Gruhn, N., et al. “Cerebral Blood Flow in Children With Chronic Heart Failure Before and After Heart Transplantation.” Stroke 32, no. 11 (2001): 2537–2544. AHA Journals.

Not Yet

No external citations. Not Yet is a narrative piece; cross-links to other One More Beat and Many Lamps, One Flame pieces only.

Outstanding Verification Notes

The following claims appear in published pieces and require citation verification or formal addition before any final citations page is published:

• Magnesium 30% absorption reduction with tacrolimus (What to Avoid and Why) — cited in clinical transplant pharmacy practice but not yet tied to a specific peer-reviewed pharmacokinetic study. The Prograf FDA prescribing information documents the magnesium-aluminum hydroxide antacid interaction without stating the 30% figure. Verify before publication.

• Marks et al. 1996 Aspergillus/transplant case (What to Avoid and Why) — referenced in secondary sources as: Marks WH, et al. Transplantation 61(12):1771–1774, 1996. Obtain direct PubMed PMID to confirm.

• Ashwagandha T-cell immune stimulation (What to Avoid and Why) — well-documented in the adaptogens literature. A transplant-specific citation is needed for this piece’s audience.

• Pearsall, Paul. The Heart’s Code (Am I Still Me?) — referenced in the piece but not formally cited. Full citation: Pearsall, Paul. The Heart’s Code. New York: Broadway Books, 1998.

• Schwartz and Russek paper (Am I Still Me?) — confirm which paper is intended before formal citation.

• Tacrolimus alopecia in The Fine Print — Krentz et al. 2005 provides the strongest peer-reviewed incidence figure. The Prograf FDA label lists alopecia as “frequency not reported.” Both citations together provide comprehensive coverage.

The Journey

I Chose Life Three Times

Twenty-Two Years…. *

The Last Decline

The Grand Parade *

The Bug Zapper

Out of the Frying Pan *

Standing On Your Own…With Assistance

Dignity

The Waiting

November 9th

Post Op / ICU

The Recovery Ward

Coming Home

The Follow-Up Gauntlet *

Life After Transplant

Return *

Brain Over Heart *

When the Dam Leaks *

The Voice *

The Year of Living Carefully

The Fine Print *

The Things You Need

Health & Management

The Blood Is the Life

The Diagnosis Nobody Prepares You For

The Long Game: Treatment, Management, and What Comes Next

Living with Immunosuppression: What the Science Actually Says

What to Avoid and Why

What We Take and Why: Immunosuppression

What We Take and Why: Supporting Cast

The Magnesium Problem

All About Tacrolimus

All About Prednisone

Glucose Management After Transplant

A Tea By Any Other Name

Opening

True Tea, One at a Time

The Citrus-Adjacent Trap

Herbal Tisanes, Individually

What’s Hiding in the Blend

A Word on Mushroom Coffee

What Your Ring Actually Knows

Heart Rate Variability and the Denervated Heart

Blood Pressure Estimation

Sleep Staging

Sleep Apnea

Single-Lead ECG

FDA Clearance and “Medical Grade”

Blood Glucose

Device Specifications

While You Were Sleeping

What Sleep Apnea Does to the Heart

After the Transplant

When the Heart Itself Changes the Breathing

Apnea, Hypopnea, and Severity

Getting Diagnosed

CPAP, APAP, BiPAP

The Wellue O2Ring-S

Caregivers Corner

A Child’s View

Reflections

Gratitude and Its Complications

And Yet

Am I Still Me?

Not Yet

Outstanding Verification Notes

Share this:

Like this: